is the Head of North America Medical Affairs at ViiV Healthcare and Professor Emeritus at Stanford University. Dr Zolopa has 20+ years of HIV experience treating patients and conducting research. He has authored or coauthored more than 100 peer-reviewed publications, dozens of textbook chapters and articles, and has held numerous leadership roles including Principal Investigator at Stanford AIDS Clinical Trials Unit.
is the head of global research and medical strategy for ViiV Healthcare. Dr. Smith oversees the clinical development of our pipeline assets in support of our overall company strategy to deliver meaningful advances in treatment and care for people living with HIV. Prior to joining ViiV Healthcare in late 2013, Dr. Smith served as the Principal Investigator of the Rush University Medical Center Clinical Research Site of the AIDS Clinical Trials Group (ACTG). Dr. Smith also served as the chair of the ACTG Underrepresented Populations committee and chair of multiple ACTG clinical trials. She has been a member of NIH study sections, the HIVMA Board of Directors, the CDC Board of Scientific Counselors and numerous advisory committees. Dr. Smith has published over 100 articles, abstracts and manuscripts and she co-edited one of the few books, HIV/AIDS in U.S. Communities of Color, which addressed the HIV epidemic among minorities in the US.
as Vice President and Global Medical Lead, Dr. Aboud leads global medical strategy for dolutegravir, including Phase IIIb/IV clinical trials, investigator-sponsored studies, and data generation and dissemination. He also provides medical oversight and governance for DTG collaborative studies, and is spearheading medical strategy for ViiV's two-drug regimen (2DR) research program. Prior to ViiV, Michael consulted for five years as Honorary HIV Consultant at Barts and The London NHS Trust where, with his high level of expertise in HIV, he provided inpatient care for those who were sickest or had complicating opportunistic infections. During this time, he also held Medical Lead positions at Janssen Therapeutics and Johnson & Johnson, managing medical strategy for HIV investigational drug programs in the UK and Ireland, including strategy for investigator-sponsored studies and data generation.
is Senior Global Medical Director at ViiV Healthcare. Prior to ViiV, she was a consulting physician in London, specializing in HIV and women and pregnancy. Dr. de Ruiter set up a service for women living with HIV, and as a result gained a significant amount of experience in the management of HIV in women and the prevention of mother-to-child transmission of HIV, with additional experience gained in caring for male patients with HIV. Involved since 2001 with development of the British HIV Association clinical practice guidelines, Annemiek served as Chair for developing the last three BHIVA guideline versions for the management of HIV positive pregnant women, in 2008, 2012, and 2014.
is a Regional Medical Director at ViiV Healthcare. He has served as an Associate Professor of Medicine the Institute of Human Virology at the University of Maryland, and has held numerous leadership positions at various Medical Centers. Dr. Gilliam has also conducted several research trails including HIV vaccine trials for the U.S. Military HIV Research Program.
is a Global Medical Director at ViiV Healthcare. Prior to ViiV, Chuck served as Director since 2014 of the well-known Owen Clinic, the HIV Medicine clinic at the University of California, San Diego. Before that, he was on faculty for more than 20 years at Duke University Medical Center, where he served as mentor, clinician, and clinical research scientist, and advanced to tenured Professor of Medicine while authoring more than 100 peer-reviewed papers. He has been an investigator in many antiretroviral treatment studies over the years, including work with the AIDS Clinical Trials Group (ACTG), and has served on a wide range of review groups and advisory panels including recent membership in the DHHS Antiretroviral Treatment Guidelines Panel.
is the Executive Medical Director North America Medical Affairs at ViiV Healthcare Dr. Joseph Mrus is an accomplished leader at ViiV Healthcare, bringing with him significant expertise in medical affairs, clinical research, clinical practice, and health outcomes. Active in the HIV arena for over twenty years, he has contributed in many ways to improved care and treatment for people living with HIV. Dr. Mrus built and now oversees the US Medical Team responsible for developing research initiatives and creating medical and patient education and support programs for ViiV’s marketed and investigational products. He also develops and implements the medical strategy for ViiV therapies, and supports the commercial organization with input, clinical review, education, and training. In addition, he leads and moderates advisory boards and conducts a myriad of other activities aimed at supporting ViiV products and ensuring integrity from a medical perspective.
is a Regional Medical Director at ViiV Healthcare and Associate Clinical Professor of Medicine at the University of California, San Francisco (UCSF). Dr Nguyen teaches and trains UCSF medical students and internal medicine residents in both general internal and HIV medicine. He also practices as a volunteer clinician at the San Francisco Department of Public Health Tom Waddell Urban Health Center in San Francisco. At his practice, Dr Nguyen has innovated ways to reduce patient waiting times, improve IT systems, initiate Pharmaceutical and Therapeutics committees, and provide better care for impoverished communities.
is Medical Director, Patient Affairs at ViiV Healthcare. As an Internal Medicine physician, Dr. Spinelli enhances his work at ViiV Healthcare with an impressive depth and breadth of experience in the greater HIV community. Recognized for his dynamic presentation and communication skills, he has a proven track record for engaging a wide variety of scientific, medical, and community audiences. Highly motivated and dedicated in his work, he brings to ViiV more than 15 years of HIV clinical practice expertise as well as clinical trial experience and a demonstrated strength in analyzing and conveying complex data. Respected for his longtime relationships with national AIDS Service Organizations and for his books and media work to address the needs of the gay community and people living with HIV, Frank is excited to be part of ViiV and its focus on creating innovative treatments and access to medicines.
is a Senior Global Medical Director at ViiV Healthcare. Respected for his extensive expertise, Dr. van Lunzen led the first HIV gene therapy study in Germany and served as principal investigator in numerous key clinical trials for treatment of HIV infection and opportunistic diseases, including studies of immune-based therapies including prophylactic and therapeutic HIV vaccines. He has authored more than 200 articles in peer-reviewed journals and is a member of the editorial board of AIDS and Journal of Virus Eradication.
is Senior Global Medical Director at ViiV Healthcare. He is the author of more than 80 journal articles, reviews and book chapters relating to HIV and its treatment. He is a member of the World Health Organization's HIV Clinical Guideline Development Group and principal investigator with the U.S. Centers for Disease Control and Prevention's HIV Outpatient Study (HOPS), a massive ongoing analysis of the health of HIV-positive people throughout the U.S. A member of the HIV Medicine Association, the International AIDS Society and the American Academy of HIV Medicine, Dr. Young is also actively involved in educating health care professionals and community groups throughout the world on HIV-related subjects.